Danilova T I, Danilov V V, Luchinskiĭ S A, Danilov V V, Vasil'chenko A V
Urologiia. 2010 Nov-Dec(6):30-4.
A 4-month course of spasmex (15 mg three times a day) was conducted in 57 females (age 18-69 years, mean age 48 years) suffering from imperative urination manifesting as pollakiuria, imperative urges and urgent urinary incontinence in combination with sexual disorders. After the treatment the score of urination disorders went down from 21.4 to 12.7. Quality of life score decreased from 4.3 to 1.7. Sexual dysfunction diminished from 3.6 to 0.8 points. Clinical data showed that spasmex has a marked effect on m-cholinoreceptors, is well tolerated, has a moderate spasmolytic effect on the smooth muscles of the lower urinary tract. Moreover, spasmex can be used for correction of female sexual dysfunction caused by overactive bladder.
对57名年龄在18至69岁（平均年龄48岁）的女性进行了为期4个月的斯帕司明治疗（每日三次，每次15毫克），这些女性患有急迫性排尿，表现为尿频、急迫性尿意和急迫性尿失禁，并伴有性功能障碍。治疗后，排尿障碍评分从21.4降至12.7。生活质量评分从4.3降至1.7。性功能障碍评分从3.6降至0.8分。临床数据表明，斯帕司明对M胆碱受体有显著作用，耐受性良好，对下尿路平滑肌有适度的解痉作用。此外，斯帕司明可用于纠正由膀胱过度活动症引起的女性性功能障碍。
